CD163 and cancer: The density of TAMs decreased with each progressive cancer stage (Supplemental Fig. 2), and locoregional cancers (stage I–III) had a higher density of CD68+ TAMs than cancers with distant metastasis (stage IV) irrespective of CD163 expression (Supplemental Fig. 3).